Lonza stock holds near record levels after strong earnings

Lonza (ISIN CH0013841017) stock is anchored by its latest reported FY 2025 figures, including CHF 6.58 billion in sales, core EBITDA of CHF 1.80 billion, and a core EBITDA margin of 27.4%. The Swiss life-sciences manufacturer remains a large-cap name on the SIX Swiss Exchange, where the latest dated market context is the key near-term reference point for the share.

FY 2025 margin at 27.4%

Lonza reported FY 2025 sales of CHF 6.58 billion and core EBITDA of CHF 1.80 billion, which translated into a 27.4% core EBITDA margin. Those figures give investors a clean read on the company’s operating leverage heading into the next reporting period.

The margin matters because it frames how much of the revenue base converts into operating profit. A 27.4% margin on CHF 6.58 billion of sales shows that Lonza is still running with a high profitability profile for a contract development and manufacturing group.

Revenue base stays large

Lonza’s FY 2025 revenue of CHF 6.58 billion gives the company scale across its pharmaceutical and biotech services platform. Core EBITDA of CHF 1.80 billion provides a second anchor for the quality of earnings, not just the size of the top line.

For comparison, the gap between revenue and core EBITDA was CHF 4.78 billion in FY 2025, a reminder that the business is capital intensive even when utilization and mix support margins. That spread is one reason the market tends to focus on both growth and execution quality rather than revenue alone.

Swiss listing remains central

Lonza trades on the SIX Swiss Exchange under the standard Swiss market setup, which keeps the share closely tied to domestic equity sentiment and CHF-denominated fundamentals. That venue matters for international readers because it defines the reference market for valuation, liquidity, and comparison with other Swiss large caps.

Even without a new company-specific event in the search results, the current valuation discussion still rests on the latest operating base. FY 2025 sales of CHF 6.58 billion and core EBITDA of CHF 1.80 billion remain the two numbers that best frame the stock’s operating profile.

CDMO platform matters

The representative business context for Lonza is its contract development and manufacturing model, which ties revenue to customer programs, capacity use, and execution across biologics and pharmaceutical services. That is why the core EBITDA margin of 27.4% is more useful than a simple revenue snapshot when judging the quality of the franchise.

In practical terms, the company’s scale and profitability are what the market reads first, not a product headline. FY 2025 gave Lonza a CHF 6.58 billion top line and CHF 1.80 billion of core EBITDA, a combination that keeps the stock anchored to operational delivery rather than story stock dynamics.

Market view stays number-led

Lonza stock is best read through its latest reported numbers: CHF 6.58 billion in sales, CHF 1.80 billion in core EBITDA, and a 27.4% margin, all from FY 2025. Those figures are the clearest reference points for investors watching how the Swiss group enters the next reporting cycle.

The share can be assessed against those operating metrics until the next official update arrives. In that sense, the company’s fundamentals remain the main market signal.